SUPN earnings call for the period ending September 30, 2019.
News & Analysis: Supernus Pharmaceuticals
Sometimes good news just isn't good enough.
Shares sell off after the company posts mixed second-quarter results. Here's what investors need to know.
Despite Supernus' strong third-quarter earnings report, two possible concerns send the stock tumbling.
A change to phase 3 trials evaluating its lead product candidate SPN-810 fueled investors' pessimism.